WebDec 16, 2024 · MARGENZA (margetuximab-cmkb) is an Fc-engineered, monoclonal antibody that targets the HER2 oncoprotein. HER2 is expressed by tumor cells in breast, gastroesophageal and other solid tumors. Similar to trastuzumab, margetuximab-cmkb inhibits tumor cell proliferation, reduces shedding of the HER2 extracellular domain and … WebMARGENZA, including treatment benefits, how it works, how it’s given, and more. Important Safety Information MARGENZA can cause serious side effects, including: • Heart problems that may affect your heart’s ability to pump blood. • Harm to your unborn baby. Tell your healthcare provider right away if you become

HER2+ Metastatic Breast Cancer Treatment MARGENZA

WebNov 1, 2024 · Administer MARGENZA as an intravenous infusion at 15 mg/kg over 120 minutes for the initial dose, then over a minimum of 30 minutes every 3 weeks for all subsequent doses. On days when both MARGENZA and chemotherapy are to be administered, MARGENZA may be administered immediately after chemotherapy … WebMARGENZA is a prescription medicine approved for use in combination with chemotherapy for the treatment of adult patients with metastatic HER2-positive breast cancer who … pss way

label - Food and Drug Administration

WebNo. Although there are many different types of breast cancer, Margenza (margetuximab) is used to treat metastatic, HER2-positive breast cancer. Your provider will perform a biopsy or surgery to remove a small piece of breast tissue. This procedure helps your provider figure out the receptor type of your cancer. Knowing what type of receptor your cancer has will … WebPrescribing Information - MARGENZA WebWithhold MARGENZA for ≥16% absolute decrease in LVEF from pretreatment values or LVEF below institutional limits of normal (or 50% if no limits available) and ≥10% absolute decrease in LVEF from pretreatment values. Permanently discontinue MARGENZA if LVEF decline persists greater than 8 weeks, or dosing is interrupted more than 3 times due ... pss wasatch supply